Zhitong Financial and Economic APP News, pre-science biology (688526.SH) issued a notice that according to the regulations on the Administration of Veterinary drugs, the measures for Registration of Veterinary drugs and other relevant provisions, after the examination of the Agriculture and Village Department of the people's Republic of China, the company developed cat rhinotracheitis, calicivirus disease, panleukopenia triple inactivated vaccine (WH-2017 strain + LZ-2016 strain + CS-2016 strain) (referred to as "cat triple vaccine") has passed the emergency evaluation organized by the Agricultural Village Department.
The company's cat triple vaccine passed the emergency evaluation organized by the Ministry of Agriculture and Village. The vaccine adopted domestic epidemic strains, filled the gap of domestic cat triple vaccine, broke the situation of long-term dependence on import of cat vaccine, solved the contradiction between fewer approved products and huge market demand, and ensured the supply of pet vaccine. In the future, this product will further enrich the range of pet vaccine products of the company, promote the diversification of the company's products and business, and have a positive impact on the promotion of the company's market competitiveness.